Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
MNTA's Cash to Debt is ranked higher than
79% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. MNTA: No Debt )
MNTA' s 10-Year Cash to Debt Range
Min: 10.74   Max: No Debt
Current: No Debt

Equity to Asset 0.85
MNTA's Equity to Asset is ranked higher than
87% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. MNTA: 0.85 )
MNTA' s 10-Year Equity to Asset Range
Min: -0.49   Max: 0.96
Current: 0.85

-0.49
0.96
Interest Coverage No Debt
MNTA's Interest Coverage is ranked higher than
84% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MNTA: No Debt )
MNTA' s 10-Year Interest Coverage Range
Min: 110.84   Max: 9999.99
Current: No Debt

110.84
9999.99
F-Score: 1
Z-Score: 6.34
M-Score: -1.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -309.01
MNTA's Operating margin (%) is ranked higher than
62% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. MNTA: -309.01 )
MNTA' s 10-Year Operating margin (%) Range
Min: -548.56   Max: 63.48
Current: -309.01

-548.56
63.48
Net-margin (%) -305.68
MNTA's Net-margin (%) is ranked higher than
62% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. MNTA: -305.68 )
MNTA' s 10-Year Net-margin (%) Range
Min: -546.42   Max: 63.71
Current: -305.68

-546.42
63.71
ROE (%) -40.18
MNTA's ROE (%) is ranked higher than
64% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. MNTA: -40.18 )
MNTA' s 10-Year ROE (%) Range
Min: -67.98   Max: 44.74
Current: -40.18

-67.98
44.74
ROA (%) -34.22
MNTA's ROA (%) is ranked higher than
65% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. MNTA: -34.22 )
MNTA' s 10-Year ROA (%) Range
Min: -194.76   Max: 42.85
Current: -34.22

-194.76
42.85
ROC (Joel Greenblatt) (%) -443.71
MNTA's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. MNTA: -443.71 )
MNTA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -562.9   Max: 372.19
Current: -443.71

-562.9
372.19
Revenue Growth (%) -34.90
MNTA's Revenue Growth (%) is ranked higher than
61% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. MNTA: -34.90 )
MNTA' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 138.6
Current: -34.9

0
138.6
» MNTA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

MNTA Guru Trades in Q2 2013

PRIMECAP Management 1,399,000 sh (+4.31%)
Steven Cohen Sold Out
Jim Simons 59,751 sh (-63.34%)
» More
Q3 2013

MNTA Guru Trades in Q3 2013

Steven Cohen 28,621 sh (New)
Paul Tudor Jones 10,600 sh (New)
PRIMECAP Management 1,505,000 sh (+7.58%)
Jim Simons Sold Out
» More
Q4 2013

MNTA Guru Trades in Q4 2013

PRIMECAP Management 1,505,000 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
» More
Q1 2014

MNTA Guru Trades in Q1 2014

Paul Tudor Jones 29,800 sh (New)
Steven Cohen 3,029,124 sh (New)
Jim Simons 425,134 sh (New)
John Burbank 12,200 sh (New)
PRIMECAP Management 2,159,414 sh (+43.48%)
» More
» Details

Insider Trades

Latest Guru Trades with MNTA

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2014-03-31 Add 43.48%0.01%$13.19 - $19.72 $ 10.96-36%2159414
John Burbank 2014-03-31 New Buy$13.19 - $19.72 $ 10.96-36%12200
Joel Greenblatt 2012-12-31 Sold Out 0.17%$10.32 - $14.82 $ 10.96-11%0
John Burbank 2012-09-30 Sold Out 0.07%$13.48 - $15.03 $ 10.96-23%0
Joel Greenblatt 2012-06-30 Add 502.05%0.13%$13.13 - $16.24 $ 10.96-26%156057
PRIMECAP Management 2012-06-30 Add 56.99%0.01%$13.13 - $16.24 $ 10.96-26%1039556
John Burbank 2012-03-31 New Buy0.08%$14.48 - $19.58 $ 10.96-28%150000
Joel Greenblatt 2012-03-31 Add 62.29%0.01%$14.48 - $19.58 $ 10.96-28%25921
Joel Greenblatt 2011-09-30 New Buy0.04%$10.62 - $20.92 $ 10.96-35%19658
PRIMECAP Management 2011-06-30 Add 866.56%0.02%$15.26 - $20.01 $ 10.96-40%724922
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.20
MNTA's P/B is ranked higher than
87% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. MNTA: 2.20 )
MNTA' s 10-Year P/B Range
Min: 1.34   Max: 14.92
Current: 2.2

1.34
14.92
P/S 14.50
MNTA's P/S is ranked higher than
75% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. MNTA: 14.50 )
MNTA' s 10-Year P/S Range
Min: 1.84   Max: 60.6
Current: 14.5

1.84
60.6
EV-to-EBIT -3.09
MNTA's EV-to-EBIT is ranked higher than
70% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MNTA: -3.09 )
MNTA' s 10-Year EV-to-EBIT Range
Min: 1.3   Max: 17.4
Current: -3.09

1.3
17.4
Current Ratio 12.45
MNTA's Current Ratio is ranked higher than
91% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. MNTA: 12.45 )
MNTA' s 10-Year Current Ratio Range
Min: 4.39   Max: 28.87
Current: 12.45

4.39
28.87
Quick Ratio 12.45
MNTA's Quick Ratio is ranked higher than
92% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. MNTA: 12.45 )
MNTA' s 10-Year Quick Ratio Range
Min: 4.39   Max: 28.87
Current: 12.45

4.39
28.87

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.20
MNTA's Price/Net Cash is ranked higher than
95% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 65.19 vs. MNTA: 3.20 )
MNTA' s 10-Year Price/Net Cash Range
Min: 2.03   Max: 14.33
Current: 3.2

2.03
14.33
Price/Net Current Asset Value 3.00
MNTA's Price/Net Current Asset Value is ranked higher than
95% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 44.88 vs. MNTA: 3.00 )
MNTA' s 10-Year Price/Net Current Asset Value Range
Min: 1.65   Max: 12.13
Current: 3

1.65
12.13
Price/Tangible Book 2.40
MNTA's Price/Tangible Book is ranked higher than
91% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. MNTA: 2.40 )
MNTA' s 10-Year Price/Tangible Book Range
Min: 1.5   Max: 10.14
Current: 2.4

1.5
10.14
Price/DCF (Projected) 4.10
MNTA's Price/DCF (Projected) is ranked higher than
92% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MNTA: 4.10 )
MNTA' s 10-Year Price/DCF (Projected) Range
Min: 1.77   Max: 5.12
Current: 4.1

1.77
5.12
Price/Median PS Value 0.70
MNTA's Price/Median PS Value is ranked higher than
92% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. MNTA: 0.70 )
MNTA' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 2.57
Current: 0.7

0.09
2.57
Earnings Yield (Greenblatt) 19.60
MNTA's Earnings Yield (Greenblatt) is ranked higher than
84% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. MNTA: 19.60 )
MNTA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.8   Max: 78
Current: 19.6

5.8
78
Forward Rate of Return (Yacktman) 1.18
MNTA's Forward Rate of Return (Yacktman) is ranked higher than
90% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. MNTA: 1.18 )
MNTA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -11   Max: -2.5
Current: 1.18

-11
-2.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:LZ1.Germany
Momenta Pharmaceuticals, Inc. was incorporated in the state of Delaware in May 2001 and began operations in early 2002. The company is a biotechnology company specializing in the structural characterization, process engineering and biologic systems analysis of complex molecules, such as polysaccharides, polypeptides, and biologics (including proteins and antibodies). The company's generics and follow-on biologics effort is focused on building a thorough understanding of the structure-process-activity of complex mixture drugs to develop generic versions of marketed products. While Momenta uses a similar analytical and development approach across all of its product candidates, it tailors that approach for each specific product candidate. The company's first objective is to apply its core analytical technology to thoroughly characterize the structure of the marketed product.Momenta's two most advanced complex generic candidates target marketed products which were originally approved by the FDA as New Drug Applications. Therefore, it was able to access the existing regulatory pathway for generic product candidates and submit an Abbreviated New Drug Application for these generic candidates. M-Enoxaparin is designed to be a technology-enabled generic version of Lovenox, a low molecular weight heparin used to prevent and treat deep vein thrombosis and to support the treatment of acute coronary syndromes. This drug is a complex mixture of polysaccharide chains derived from naturally sourced heparin. The company's second major generic product candidate is M356, a technology-enabled generic version of Copaxone, a drug that is indicated for the reduction of the frequency of relapses in patients with Relapse-Remitting Multiple Sclerosis. Copaxone consists of a complex mixture of polypeptide chains. With M356, it has extended its core characterization capabilities from the characterization of complex polysaccharide mixtures to include the characterization of complex polypeptide mixtures. In addition to Momenta's two complex generic product candidates, which are both currently under review by FDA, it has further extended its analytical and development platform to pursue generic or follow-on versions of biologic drugs. The company's efforts on M178, as well as its ongoing Glycoprotein Research Program, are focused on developing generic or follow-on versions of marketed therapeutic proteins which are derived from natural or cell based manufacturing processes.
» More Articles for MNTA

Headlines

Articles On GuruFocus.com
Very Low P/E Stocks Joel Greenblatt selected Dec 22 2011 
Momenta Pharmaceuticals Inc. (MNTA) SVP, CFO Richard P Shea sells 979 Shares Feb 24 2011 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 45,296 Shares Aug 05 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 7,800 Shares Mar 12 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 32,200 Shares Mar 10 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 1,413 Shares Mar 03 2010 

More From Other Websites
Limited downside seen in Momenta Jul 22 2014
MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jul 18 2014
Momenta Pharmaceuticals Announces Date of Second Quarter 2014 Financial Results Conference Call and... Jul 15 2014
Earnings Estimates Moving Higher for Momenta Pharmaceuticals (MNTA): Time to Buy? Jun 20 2014
MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 17 2014
Pipeline Progress at Momenta Jun 09 2014
Momenta Pharmaceuticals to Webcast Presentation at the Wells Fargo Healthcare Conference Jun 09 2014
Momenta Pharma coverage assumed with a Buy at Maxim Jun 05 2014
Momenta Pharmaceuticals Receives Orphan Drug Designation for Necuparanib (Formerly M402) in... Jun 05 2014
Momenta Pharmaceuticals (MNTA) 2014 UBS Global Healthcare Conference (Transcript) May 20 2014
Momenta generic of Copaxone seen launching by June, says Maxim May 15 2014
Teva loses bid to block approval of generic Copaxone, Bloomberg reports May 14 2014
Teva loses in effort to block generic Copaxone, Bloomberg reports May 14 2014
MOMENTA PHARMACEUTICALS INC Financials May 14 2014
Momenta Pharmaceuticals Management Presents at Bank of America Merrill Lynch Health Care Conference... May 13 2014
Momenta Pharmaceuticals' CEO Presents at Deutsche Bank 39th Annual Health Care Conference -... May 11 2014
Momenta Pharma initiated with a Buy at Maxim May 09 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide